Aristoteles Giagounidis

发表

Treatment of relapsed idiopathic thrombocytopenic purpura with the anti‐CD20 monoclonal antibody rituximab: a pilot study

U. Germing, C. Aul, D. Söhngen, 2002, European journal of haematology.

Imatinib compared with chemotherapy as front‐line treatment of elderly patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ALL)

U. Dührsen, O. Ottmann, L. Wunderle, 2007, Cancer.

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.

A. Krämer, K. Kreuzer, J. Duyster, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study

T. Brümmendorf, A. Kiani, A. Fabarius, 2023, Annals of Hematology.

Satelite Symposium V, Meet-the-Professor Sessions I and II, Main Sessions I-IX

W. Kern, H. Serve, L. Balleisen, 2004, Annals of Hematology.

Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study.

M. Tallman, S. Koschmieder, A. Schimmer, 2011, Clinical lymphoma, myeloma & leukemia.

STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2.

M. Sekeres, V. Santini, A. Zeidan, 2023, Future oncology.

Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox

C. Haferlach, J. Schlué, A. Giagounidis, 2016, Oncology Research and Treatment.

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload

C. Schumann, M. Taupitz, W. Hofmann, 2012, Annals of Hematology.

Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)

C. Steidl, M. Lübbert, C. Fonatsch, 2005, Leukemia.

Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes.

M. Lübbert, P. Valent, M. Pfeilstöcker, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses

K. Götze, M. Fey, W. Brugger, 2012, Leukemia.

Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2012 .

Compassionate Use of Sorafenib in Relapsed and Refractory Flt3-ITD Positive Acute Myeloid Leukemia.

S. Scholl, A. Reiter, A. Neubauer, 2009 .

Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.

W. Klapper, C. Franzius, K. Jöckel, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.

H. Einsele, M. Görner, A. Mackensen, 2015, The Lancet. Oncology.

Baseline and interim PET‐based outcome prediction in peripheral T‐cell lymphoma: A subgroup analysis of the PETAL trial

W. Brenner, R. Boellaard, W. Klapper, 2020, Hematological oncology.

Sorafenib Versus Placebo in Addition to Standard Therapy in Adult Patients ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia: Results From the Randomized-Controlled Soraml Trial

A. Krämer, A. Hüttmann, W. Berdel, 2012 .

Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia

C Haferlach, W Hiddemann, T Haferlach, 2016, Leukemia.

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

R. Schlenk, A. Ganser, K. Götze, 2012, Leukemia.

Epidemiological Features of Myelodysplastic Syndromes: Results From Regional Cancer Surveys and Hospital-Based Statistics

U. Germing, C. Aul, A. Giagounidis, 2001, International journal of hematology.

Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia

N. Schmitz, J. Gerss, T. Brümmendorf, 2016, Leukemia.